Merck Pharmaceutical

About Merck Pharmaceuticals

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.

Merck Research

An unrelenting focus on breakthrough science has helped Merck researchers bring many important medicines to market. Research is the foundation of Merck's success and the heart of our company's overall strategy. Our research is conducted in a broad range of therapeutic categories.

Merck is dedicated to staying at the forefront of discovery with a commitment to research and development. These resources allow Merck to stay at the forefront of discovery. Merck scientists use the most advanced tools available, including bioinformatics, combinatorial chemistry, genomics, high-throughput screening, pharmacogenomics, recombinant DNA techniques, and computerized molecular modeling. These resources allow Merck to stay at the forefront of discovery.

Pharmaceutical Sciences

The Pharmaceutical Sciences, a scientific discipline custom-tailored to drug development, is represented at MRL in the Pharmaceutical Research and Development (PR&D) and Drug Metabolism Departments. To support appropriate delivery of Merck's new medicines and vaccines, expertise in pharmaceutics and pharmacokinetics is used in PR&D to guide the development of drug formulations, packaging and devices. These same techniques are used in Drug Metabolism to study the absorption, distribution, metabolism and elimination of drug candidates in biological systems.

MSD in the UK

Merck Sharp & Dohme Ltd is the UK subsidiary of the global, research-driven pharmaceutical company Merck & Co., Inc. Merck & Co. Inc discovers, develops, manufactures and markets a range of products to improve human health.

MSD has committed substantial long-term investment to research and manufacturing in the UK because of the unrivalled scientific excellence and skills base available here. It has four sites in the UK :- headquarters at Hoddesdon, Hertfordshire, research at Terlings Park in Essex, and manufacturing at Cramlington in Northumberland and Ponders End in Enfield.

Merck Sharp and Dohme Limited is the UK subsidiary of Merck & Co., Inc., a global pharmaceutical company. Merck & Co., Inc. merged with UK partnership Sharp & Dohme in 1953 to create MSD. MSD has discovered eight products in the UK, which are among Merck’s most popular medicines. MSD is headquartered in Hoddesdon, Hertfordshire and employs approximately 2000 people in the UK. It has three other sites in the UK – Terlings Park in Essex, Cramlington in Northumberland and Ponders End in Enfield. Around 18 medicines are manufactured in the UK by MSD. UK sales amounted to £451 million in 2004. MSD has invested £290 million in the UK between 2002 and 2005. Over £300 million per year is spent on research by MSD.

Latest Merck Pharmaceutical news

Reports ISENTRESS® (raltegravir), Merck's First in Class Integrase Inhibitor, Suppressed HIV-1 Viral Load and Increased CD4 Cell Counts through 48-Weeks in Treatment-Experienced Adult Patients When Taken with Other Anti-HIV Medicines. Merck Responds to Questions about Adverse Events Reported following Vaccination with GARDASIL®. CDC Observes Reduction in Rotavirus Disease After the Introduction of ROTATEQ®, Merck's Rotavirus Vaccine. Merck Announces Fourth Quarter 2008 Dividend. Merck Reports Second-Quarter 2008 Financial Results. Merck Will Hold Second-Quarter 2008 Sales and Earnings Conference Call and Webcast at 5:30 PM (EDT) on July 21. Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase III Study. Schering-Plough And Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture. Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin). Pharma giants to collaborate on new discovery tech. Merck, Schering-Plough end respiratory collaboration. Study projects new wave of globalization in biopharma. Daiichi Sankyo acquires Ranbaxy in $4.6B deal. DPP-4 inhibitors get spotlight at ADA meeting. Merck's osteoporosis drug performs in Phase II. read more

Wyeth further information:
www.merck.com | www.msd-uk.com | Merck news

Page last updated: 05/06/08

Pharmaceutical product information and articles
Get the latest Pharmaceutical drug reviews, reports & pharmaceutical intelligence


Contact \| Suggest Pharmaceutical Resource	Copyright © Net Media Marketing. All rights reserved.

Pharmaceutical jobs, Medical / Pharmaceutical sales jobs, Pharmaceutical Company, Pharmaceutical, Pharmajobs, Pharma jobs, Pharmaceutical sales Pharmaceutical jobs, Healthcare sales, Laboratory sales, Veterinary sales jobs, Dental sales jobs, Trainee sales jobs, Nurse Advisor jobs, Sales Management, Pharma Marketing, Senior Management, Regulatory & Clinical & Scientific sales jobs